Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02053935 · ClinicalTrials.gov registry record · Phase 1

Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects

A Phase 1 study, sponsored by Albert Einstein College of Medicine.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target

NCT02053935: Completed Phase 1 study, sponsored by Albert Einstein College of Medicine.

NCT02053935 is a Phase 1 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02053935, a Phase 1 study, has completed, sponsored by Albert Einstein College of Medicine.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target

Study Summary

This is a clinical study of a drug named dopamine and how it affects our bodies ability to make and secrete insulin. Insulin is a hormone made in the pancreas that helps our body regulate sugar levels. We think that this drug decreases the amount of insulin our body makes and causes our sugar levels to be high. When you are critically ill there can be many adverse effects if you have sugar levels that are too high.

Primary Outcome

Insulin secretion will be assessed via glucose infusion requirement during a hyperglycemic clamp. Insulin and c-peptide levels will be monitored. Insulin secretion will be attenuated by 30% from baseline in subjects receiving dopamine

Interventions

  • DRUG Dopamine

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2013-12
Est. Completion 2016-01
Phase Phase 1
Albert Einstein College of Medicine

175 total trials

What the finished NCT02053935 record still lists

NCT02053935 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 1 intervention - of which Dopamine is the first listed.

NCT02053935 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02053935 about?

NCT02053935 is a clinical study titled "Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects". This is a clinical study of a drug named dopamine and how it affects our bodies ability to make and secrete insulin. Insulin is a hormone made in the pancreas that helps our body regulate sugar levels. We think that this drug decreases the amount of insulin our body makes and causes our sugar levels...

What is the current status of trial NCT02053935?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-12. Estimated completion is 2016-01.

What interventions are being tested in trial NCT02053935?

The interventions under investigation include: Dopamine (DRUG).

Who is sponsoring clinical trial NCT02053935?

This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02053935's enrollment target sits among peer trials

15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02053935, the US trial registry maintained by the National Library of Medicine. NCT02053935 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.